A targeted drug delivery technology
Indication
Cancer
Development status
Preclinical
Patents
U.S. and Patent Cooperation Treaty applications filed
Partner
Available for licensing
Cancer - NGR-Delivery Technology
Ambrilia has developed a targeted delivery technology that uses a proprietary peptide coupled with a carrier. This peptide specifically binds to a receptor expressed by many tumor cells which in turn triggers internalization of the carrier’s load into the cell.
Established proof of concepts
The Company has established a proof-of-concept with doxorubicin, a cytotoxic drug, showing its efficient delivery in animal solid tumor models. Also, a second proof-of-concept was demonstrated with a siRNA, showing efficient delivery to tumor cells in vitro and in vivo.
Data in animal tumor models showed efficient siRNA delivery to the tumor tissue, internalization and suppression of a cancer-promoting gene (oncogene). Such genes are essential to the growth of a number of tumors. In the past years, a number of oncogenes have been suppressed with RNA interference (RNAi), which can be achieved by siRNAs, showing the potential for therapeutic applications in humans.
Licensing opportunities
Ambrilia's NGR-Delivery Technology is available for licensing. For more information please contact:
Daniel Böck, Ph.D.
Vice-President, Business Development and Licensing
Tel.: 514 751-2003 ext. 236
E-mail: dbock@ambrilia.com
